📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-28 18:58
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
86 announcements match the current filters (relevance ≥ 5).
Clean Max Approves Term Sheet to Procure 1,550 MW Wind Turbines from Envision Energy
Clean Max Enviro Energy Solutions has approved the execution of a term sheet with Envision Energy India Private Limited to procure wind turbine generators for an aggregate capacity of 1,550 MW. Under the agreement, the company will procure 310 wind turbine generators of 5 MW each along with installation supervision and commissioning support. Definitive agreements for the procurement are scheduled to be executed in seven phases concluding before December 31, 2028.
Confidence: HIGH
What changedClean Max's Risk Management Committee approved a term sheet to procure 1,550 MW of wind turbines from Envision Energy India.
Why it mattersSecures turbine equipment supply for a massive 1.55 GW wind portfolio, providing clear visibility on project execution and capacity expansion through FY29.
Total Capacity: 1,550 MWTotal WTG Units: 310Turbine Rating: 5 MW eachPhases of Execution: 7 phasesTarget Completion Date: 31 December 2028Contract Value: not disclosed
📅 Short termPositive sentiment from securing major equipment supply for renewable capacity pipeline.
📈 Long termAdds 1,550 MW of generation assets by end-2028, which will substantially scale up the company's operating revenue and clean energy output.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk across 7 phases spread until December 2028
- Commercial value and capex funding details not disclosed in the term sheet
Key Highlights
Approved procurement term sheet for 1,550 MW aggregate wind power capacity
Procuring 310 wind turbine generators (WTGs) rated at 5 MW each from Envision Energy India
Execution of definitive agreements planned across 7 phases ending before 31 December 2028
Includes supervision, technical support for installation, and commissioning services
👀 What to Watch
Track the signing of definitive phase-wise agreements and project commissionings through December 2028, along with financing announcements for the 1,550 MW capacity buildout.
Rs 55 Cr PAT and 500 MW Capacity Added in Q1 FY27; EBITDA Guidance of Rs 3,000 Cr by FY28
CleanMax reported a strong Q1 FY27 with PAT reaching Rs 55 cr, driven by doubling revenues and significant margin expansion. The company added 500 MW of capacity in the quarter, keeping it on track for its 1.5 GW annual guidance. Management provided an ambitious FY28 EBITDA target of Rs 3,000 cr, which is 2.4x the FY26 level of Rs 1,290 cr. The company maintains a dominant 35% market share in the hyperscaler segment, serving global giants like Meta, Google, and Amazon.
Confidence: HIGH
What changedThe company has provided a clear multi-year growth roadmap with specific EBITDA targets and demonstrated significant operational leverage through margin expansion.
Why it mattersCleanMax is a key beneficiary of the Data Center/AI boom in India, with 42% of its capacity serving hyperscalers; its ability to lower borrowing costs while scaling capacity is a major competitive advantage.
Q1 FY27 PAT: Rs 55 crFY28 EBITDA Guidance: Rs 3,000 crQ1 Capacity Addition: 500 MWHyperscaler Market Share: 35%Current Interest Rate: 8.4%Operational Portfolio Tariff: Rs 3.93 per unit
📅 Short termThe stock may react positively to the strong margin improvement and the robust 1.5 GW capacity addition guidance for the current fiscal year.
📈 Long termThe structural shift toward green energy for industrial and data center clients provides a long runway, especially with the company's 6.8 GW total portfolio and high repeat business (80%).
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the 2.5 GW under-construction pipeline
- Regulatory changes in state-level open access policies
Key Highlights
PAT reached Rs 55 cr in Q1 FY27, supported by a 74% YoY increase in EBITDA to Rs 494 cr
Added 500 MW of new capacity in Q1, with a total contracted portfolio now at 6.8 GW
EBITDA margins in the RE Power Sales segment improved from 76% to 84% YoY
Weighted average interest rate reduced by 100 bps from 9.4% in April 2025 to 8.4% in June 2026
Management guided for a minimum EBITDA of Rs 3,000 cr by FY28, up from Rs 1,290 cr in FY26
👀 What to Watch
Watch for the execution of the 2.5 GW under-construction pipeline and the upcoming first-ever domestic corporate bond issuance following the credit rating upgrade to AA-.
Rs 264 Cr Record Revenue: Clean Science Reports 10% YoY Growth Driven by HALS Ramp-up
Clean Science and Technology reported its highest-ever consolidated quarterly revenue of Rs 264 Cr in Q1 FY27, a 10% YoY increase. The growth was primarily driven by the HALS (Hindered Amine Light Stabilizers) segment, which now contributes 22% of total sales, up from 15% previously. The company announced a strategic collaboration with Swiss partner Geneus Chem for advanced HALS grades, targeting an additional Rs 300-350 Cr revenue over the next 3-4 years. While legacy products saw a 6% YoY volume decline due to supply chain headwinds, the subsidiary CFCL has reached operational self-sufficiency.
Confidence: HIGH
What changedThe company's subsidiary (CFCL) has transitioned from an investing phase to a monetizing phase, and the HALS business has successfully diversified into export markets.
Why it mattersThis shift reduces the company's reliance on its four legacy products and introduces higher-margin, technology-intensive chemistries that could improve overall profitability and market positioning.
Consolidated Revenue (Q1 FY27): Rs 264 CrHALS Revenue Contribution: 22%Subsidiary Investment vs Market Cap: ~10.4%HALS Volume (Q1): 1,000 tonsTarget Revenue from Swiss Partnership: Rs 300-350 Cr
📅 Short termThe record revenue and operational break-even of the subsidiary are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe structural shift toward advanced HALS and performance chemicals provides a clear path for revenue diversification and long-term growth beyond legacy phenol derivatives.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Volatility in crude-linked raw material prices
- Non-availability of shipping vessels impacting exports
- Execution risk in the new Swiss technology partnership
Key Highlights
Consolidated revenue reached a record Rs 264 Cr, representing a 10% YoY growth.
HALS segment now accounts for 22% of total sales, reducing legacy product dependence from 85% to 60%.
Strategic collaboration with Geneus Chem (Switzerland) targets Rs 300-350 Cr in additional revenue over 3-4 years.
Total capital infusion in the subsidiary stands at approximately Rs 850 Cr, which is ~10.4% of the current market cap.
HALS export mix improved to nearly 50% of segment sales, compared to being entirely domestic in the first year.
👀 What to Watch
Watch for the commercialization of Performance Chemical 2 in Q3 FY27 and the execution of the Geneus Chem partnership to see if it meets the Rs 300 Cr+ revenue target.
Rs 268 Cr Revenue in Q1 FY27; HALS Contribution Rises to 22% Amid Margin Pressure
Clean Science reported an 11% YoY growth in consolidated revenue to Rs 268 Cr for Q1 FY27, driven by the ramp-up of the HALS portfolio. However, consolidated EBITDA margins compressed to 36.5% from 41.6% YoY, primarily due to raw material costs rising to 39.7% of sales. The company invested Rs 100 Cr in its subsidiary CFCL during the quarter, representing approximately 11.3% of TTM revenue. A significant structural shift is underway as HALS now contributes 22% of sales, successfully reducing legacy product concentration from 85% to 60%.
Confidence: HIGH
What changedThe company is transitioning from a legacy-product-heavy portfolio to a more diversified specialty chemical player, with HALS becoming a major revenue driver.
Why it mattersThis diversification reduces the risk associated with price volatility in core products like MEHQ and Guaiacol, while the ongoing capex signals a focus on high-value performance chemicals to drive future growth.
Q1 FY27 Consolidated Revenue: Rs 268 CrQ1 FY27 EBITDA Margin: 36.5%Q1 Capex vs TTM Revenue: ~11.3%HALS Sales Contribution: 22%Raw Material Cost % of Sales: 39.7%
📅 Short termThe stock may face pressure due to the 510 bps YoY compression in EBITDA margins, despite the double-digit revenue growth.
📈 Long termThe structural shift toward HALS and the expansion into Europe suggest a long-term strategy to scale the business and reduce dependence on a few key molecules.
⚠ Risk flags
- Margin compression due to rising raw material costs
- Execution risk for the Performance Chemical 2 facility
- Global headwinds affecting export realizations
Key Highlights
Consolidated revenue increased 11% YoY to Rs 268 Cr in Q1 FY27
HALS segment now accounts for 22% of total sales, up from 0% in FY23
Incurred Rs 100 Cr capex in Q1 FY27 towards subsidiary Clean Fino Chem Ltd
Top 4 legacy products concentration reduced to 60% from 85% in Q4 FY23
Performance Chemical 2 facility expected to be commercialized by Q3 FY27
👀 What to Watch
Monitor the margin trajectory in upcoming quarters to see if the company can pass through higher raw material costs. Watch for the successful commercialization and ramp-up of the Performance Chemical 2 unit scheduled for Q3 FY27.
Clean Science Q1 Revenue Hits ₹268 Cr; Appoints New WTD and Expands to Netherlands
Clean Science and Technology reported a strong Q1 FY27 with revenue reaching ₹268.43 Cr, a 36% sequential increase from ₹197.13 Cr in the previous quarter. The company has appointed Mr. Krishnakumar Satyanarain Saboo, an 11-year veteran of the firm, as a Whole-time Director for a five-year term to lead operations and new projects. Furthermore, the board approved the incorporation of a wholly-owned subsidiary in the Netherlands with an initial capital of EUR 50,000 to handle European distribution. A final dividend for FY26 has been confirmed with a record date of September 5, 2026.
Confidence: HIGH
What changedThe company has transitioned a senior operational leader to the Board and initiated a direct corporate presence in Europe for distribution.
Why it mattersThe sequential revenue jump suggests a recovery in demand or successful ramp-up of the HALS portfolio. Direct European presence aims to improve realizations by reducing dependence on intermediaries.
Q1 FY27 Revenue: ₹268.43 CrQ1 FY27 PAT: ₹66.28 CrRevenue vs TTM Revenue: 30.4%Netherlands Sub Capital: EUR 50,000Dividend Record Date: 5th September 2026
📅 Short termThe stock may see positive momentum due to the sharp sequential recovery in revenue and profit compared to the March 2026 quarter.
📈 Long termThe appointment of an internal operations head to the board and international expansion support the company's long-term strategy of diversifying its product basket and global reach.
⚠ Risk flags
- Volatility in crude-linked raw material prices
- Execution risk in the new international distribution entity
Key Highlights
Q1 FY27 Revenue stood at ₹268.43 Cr, representing approximately 30% of the total TTM revenue of ₹882 Cr.
Net Profit for the quarter improved to ₹66.28 Cr, up from ₹58.12 Cr in the March 2026 quarter.
Appointment of Mr. Krishnakumar Satyanarain Saboo as Whole-time Director for 5 years (Aug 2026 - July 2031).
Incorporation of a new subsidiary in the Netherlands with an initial capital of EUR 50,000 (approx. ₹46 Lakhs).
Final dividend payment scheduled for September 30, 2026, following the AGM on September 12, 2026.
👀 What to Watch
Investors should monitor the margin sustainability as revenue scales and track the progress of the Netherlands subsidiary in improving direct sales to global accounts.
Clean Science Q1 Revenue up 21% QoQ to Rs 268 Cr; PAT down 13% as margins compress
Clean Science and Technology reported Q1 FY27 consolidated revenue of Rs 268.43 cr, a 20.8% sequential increase from Rs 222.18 cr in Q4 FY26. However, net profit declined 13.2% QoQ to Rs 50.46 cr, indicating significant margin pressure compared to the previous quarter's Rs 58.12 cr. The company is expanding its global footprint by incorporating a wholly-owned subsidiary in the Netherlands with an initial capital of EUR 50,000. Additionally, the board has appointed Mr. Krishnakumar Saboo, a veteran with 11 years at the firm, as a Whole-time Director for a 5-year term.
Confidence: HIGH
What changedClean Science reported its Q1 FY27 results, announced a new international subsidiary in the Netherlands, and elevated a senior operations head to the Board of Directors.
Why it mattersThe revenue growth suggests successful capacity utilization of new units, but the sharp decline in PAT (down 34% YoY) indicates that pricing power or raw material costs remain a challenge. The new European subsidiary signals a strategic move to handle global distribution directly.
Q1 FY27 Revenue: Rs 268.43 crQ1 FY27 PAT: Rs 50.46 crQoQ Revenue Growth: 20.8%YoY PAT Growth: -34.1%Subsidiary Capital vs TTM Revenue: ~0.05%
📅 Short termThe stock may face pressure due to the sequential and year-on-year decline in net profit despite the revenue beat. The market will likely focus on the margin contraction.
📈 Long termThe company's expansion into the Netherlands and the appointment of an operations-focused director support its long-term strategy of global distribution and manufacturing efficiency, though margin recovery is key.
⚠ Risk flags
- Significant margin compression (PAT down despite higher revenue)
- Raw material price volatility affecting realizations
- High P/E of 33.0 relative to declining profit growth
Key Highlights
Consolidated Revenue for Q1 FY27 stood at Rs 268.43 cr, showing a 22% growth over the same quarter last year (Rs 219.91 cr).
Net Profit for the quarter was Rs 50.46 cr, down 34% YoY from Rs 76.57 cr in June 2025.
Final dividend record date fixed for September 5, 2026, with payment scheduled for September 30, 2026.
New Netherlands subsidiary to be established for distribution and trading with an initial capital of EUR 50,000.
Mr. Krishnakumar Saboo appointed as Whole-time Director and Factory Occupier from August 1, 2026, to July 31, 2031.
👀 What to Watch
Investors should monitor the operating profit margin (OPM) trajectory, as the current quarter shows a disconnect between strong revenue growth and declining profitability. Watch for management commentary on raw material costs and the ramp-up of the HALS series in the upcoming AGM on September 12, 2026.
Clean Science Q1 Revenue Grows 36% QoQ to ₹268 Cr; New Netherlands Subsidiary Announced
Clean Science and Technology reported a strong sequential recovery in Q1 FY27 with consolidated revenue reaching ₹268.43 Cr, up 36% from ₹197.13 Cr in Q4 FY26. Net profit for the quarter stood at ₹50.46 Cr, though it remains lower than the ₹58.12 Cr reported in the previous quarter, suggesting margin pressure. The company is expanding its global footprint by incorporating a wholly-owned subsidiary in the Netherlands with an initial capital of EUR 50,000. Additionally, the board has appointed Mr. Krishnakumar Saboo, a company veteran of 11 years, as a Whole-time Director for a five-year term.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial results, initiated a direct European presence via a new Netherlands subsidiary, and elevated its Group President (Operations) to the Board of Directors.
Why it mattersThe sequential revenue growth indicates a potential turnaround from the previous quarter's lows. The Netherlands subsidiary is a strategic move to increase direct sales to global accounts, potentially improving long-term realizations.
Q1 FY27 Revenue: ₹268.43 CrQ1 FY27 Net Profit: ₹50.46 CrRevenue Growth (QoQ): 36.1%Subsidiary Initial Capital: EUR 50,000Dividend Record Date: September 5, 2026
📅 Short termThe stock may see positive momentum due to the sharp sequential recovery in revenue, although the slight dip in PAT compared to Q4 FY26 might temper the enthusiasm.
📈 Long termThe company's focus on new chemistries (HALS) and direct global distribution through the new European arm supports its 25% growth target, provided it can maintain its industry-leading margins.
⚠ Risk flags
- Margin compression (PAT declined despite revenue growth)
- Volatility in crude-linked raw material prices
- Time lag in passing through cost increases
Key Highlights
Consolidated Revenue for Q1 FY27 stood at ₹268.43 Cr, a significant jump from ₹197.13 Cr in the preceding quarter.
Net Profit for the quarter reported at ₹50.46 Cr with an EPS of ₹4.75.
Incorporation of a new subsidiary in the Netherlands with an initial capital of EUR 50,000 to handle European distribution and trading.
Final dividend record date fixed for September 5, 2026, with payment scheduled for September 30, 2026.
Appointment of Mr. Krishnakumar Saboo as Whole-time Director for a 5-year tenure effective August 1, 2026.
👀 What to Watch
Investors should monitor the operating margins in upcoming quarters to see if the revenue growth translates into higher profitability. Watch for the execution of the ₹300 Cr FY26 capex plan and the ramp-up of the HALS portfolio.
Clean Science Q1 Revenue at ₹268.4 Cr; Sets Sept 5 as Dividend Record Date
Clean Science and Technology reported Q1 FY27 consolidated revenue of ₹268.43 cr and a PAT of ₹66.28 cr, showing sequential growth over the March 2026 quarter. The Board has fixed September 5, 2026, as the record date for the final dividend, with payment scheduled for September 30, 2026. Additionally, the company is expanding its global footprint by incorporating a wholly-owned subsidiary in the Netherlands with an initial capital of EUR 50,000. Mr. Krishnakumar Satyanarain Saboo has been appointed as a Whole-time Director for a five-year term to lead operations.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, formalized dividend timelines, and initiated an international corporate structure expansion into Europe.
Why it mattersThe sequential revenue growth (₹268.4 cr vs ₹197.1 cr in Mar 2026) suggests a recovery in demand or realization; the Netherlands subsidiary indicates a strategic shift toward direct international sales and job work.
Q1 FY27 Revenue: ₹268.43 crQ1 FY27 PAT: ₹66.28 crDividend Record Date: September 5, 2026Subsidiary Initial Capital: EUR 50,000Q1 Revenue vs TTM Revenue: 30.4%
📅 Short termThe stock may react to the sequential improvement in revenue and the clarity on dividend timelines over the coming weeks.
📈 Long termThe appointment of an experienced operations head and the European expansion are structural positives, though the initial scale of the foreign subsidiary is small.
⚠ Risk flags
- Volatility in crude-linked raw material prices
- Execution risk in new international markets
Key Highlights
Consolidated Revenue for Q1 FY27 stood at ₹268.43 cr, representing approximately 30.4% of TTM revenue.
Consolidated Profit After Tax (PAT) for the quarter ended June 30, 2026, was ₹66.28 cr.
Record date for final dividend entitlement fixed for September 5, 2026.
Incorporation of a new subsidiary in the Netherlands with an initial capital infusion of EUR 50,000.
Appointment of Mr. Krishnakumar Satyanarain Saboo as Whole-time Director for a 5-year term starting August 1, 2026.
👀 What to Watch
Investors should monitor the sequential margin recovery and the progress of the Netherlands subsidiary in establishing direct global distribution channels.
Clean Science Q1 PAT at ₹61.1 Cr; Netherlands Subsidiary & New WTD Appointed
Clean Science and Technology reported a strong sequential recovery in Q1 FY27, with revenue reaching ₹268.43 cr, up ~36% from ₹197.13 cr in Q4 FY26. Net profit for the quarter stood at ₹61.11 cr, a 5.1% increase over the previous quarter. The company is expanding its global footprint by incorporating a wholly-owned subsidiary in the Netherlands with an initial capital of EUR 50,000 to handle international distribution. Additionally, the board has elevated Mr. Krishnakumar Satyanarain Saboo, a 37-year industry veteran, to Whole-time Director for a five-year term.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, initiated the setup of a European subsidiary, and promoted its Group President (Operations) to the Board of Directors.
Why it mattersThe sharp sequential revenue growth suggests a successful ramp-up of new capacities or improved demand in specialty chemicals. The Netherlands subsidiary indicates a strategic shift toward direct global distribution to improve realizations.
Revenue (Q1 FY27): ₹268.43 crPAT (Q1 FY27): ₹61.11 crQoQ Revenue Growth: 36.2%Subsidiary Initial Capital: EUR 50,000Dividend Record Date: September 5, 2026
📅 Short termThe strong sequential revenue growth and the formalization of the dividend timeline are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe establishment of a European base and the elevation of operational leadership support the company's long-term goal of diversifying its product basket and increasing direct global sales.
⚠ Risk flags
- Volatility in crude-linked raw material prices (Phenol)
- Execution risk in the new international distribution entity
Key Highlights
Revenue for Q1 FY27 stood at ₹268.43 cr, showing a significant sequential jump from ₹197.13 cr in Q4 FY26.
Net Profit for the quarter reached ₹61.11 cr, compared to ₹58.12 cr in the preceding quarter.
Incorporation of a new subsidiary in the Netherlands with an initial capital of EUR 50,000 (approx. ₹46 lakhs) for global sales and distribution.
Appointment of Mr. Krishnakumar Satyanarain Saboo as Whole-time Director for a 5-year tenure starting August 1, 2026.
Final dividend record date confirmed as September 5, 2026, with payment scheduled for September 30, 2026.
👀 What to Watch
Investors should monitor the revenue contribution from the HALS series in upcoming quarters to see if the Q1 growth momentum is sustainable. The AGM on September 12, 2026, will be a key event for further management commentary on the European expansion strategy.
Clean Science Q1 FY27 Revenue at ₹268.4 Cr; New Netherlands Subsidiary Approved
Clean Science reported a strong start to FY27 with consolidated revenue of ₹268.43 cr, a significant sequential increase from ₹197.13 cr in Mar 2026. The company maintained healthy profitability with a PAT of ₹66.28 cr for the quarter. The board also approved the incorporation of a new wholly-owned subsidiary in the Netherlands with an initial capital of EUR 50,000 to facilitate international distribution. Additionally, operations veteran Mr. Krishnakumar Saboo has been appointed as a Whole-time Director for a five-year term.
Confidence: HIGH
What changedThe company has reported a sharp sequential revenue increase and initiated a direct corporate presence in Europe through a new subsidiary.
Why it mattersThe revenue jump indicates successful scaling of new product lines or recovery in core specialty chemicals. The Netherlands entity will likely reduce dependence on third-party distributors in the European market.
Q1 FY27 Revenue: ₹268.43 crQ1 FY27 PAT: ₹66.28 crQ1 Revenue vs TTM Revenue: 30.4%Subsidiary Initial Capital: EUR 50,000Dividend Record Date: 05.09.2026
📅 Short termThe stock may see positive sentiment due to the strong sequential revenue growth compared to the March 2026 quarter.
📈 Long termThe expansion into direct European distribution and the appointment of an operations-focused director align with the company's long-term strategy to diversify its product basket and global reach.
⚠ Risk flags
- Volatility in crude-linked raw material prices
- Execution risk in the new international distribution subsidiary
Key Highlights
Consolidated Revenue for Q1 FY27 reached ₹268.43 cr, representing approximately 30.4% of the total TTM revenue.
Net Profit for the quarter stood at ₹66.28 cr, showing recovery from the ₹58.12 cr reported in the preceding quarter.
Final dividend record date set for September 5, 2026, with payment scheduled by September 30, 2026.
New European subsidiary to be incorporated in the Netherlands with an initial capital infusion of EUR 50,000.
Appointment of Mr. Krishnakumar Saboo (37+ years experience) as Whole-time Director effective August 1, 2026.
👀 What to Watch
Investors should monitor the revenue contribution from the HALS series and the efficiency of the new Netherlands subsidiary in expanding global market share. The sequential growth in revenue suggests improved utilization of Unit 4 capacities.
Clean Science Signs 5-Year Strategic Supply Deal with Kemin Industries
Clean Science and Technology Limited (CSTL) has entered into a long-term strategic supply arrangement with Kemin Industries for the food and feed sector. Under this 5-year agreement, CSTL will act as a substantial primary supplier of key ingredients, likely leveraging its leadership in products like BHA. This move aligns with the company's strategy to diversify its product basket and increase direct sales to global accounts. While the specific contract value is not disclosed, it provides revenue visibility following a period where TTM revenue declined to ₹882 Cr from ₹929 Cr in FY25.
Confidence: MEDIUM
What changedCSTL has transitioned from transactional sales to a formal, 5-year primary supplier relationship with a major global player in the food and feed industry.
Why it mattersThis partnership provides long-term volume security and validates CSTL's competitive position in specialty ingredients, helping to mitigate the impact of volatile realizations seen in its core MEHQ business.
Initial Contract Term: 5 yearsTTM Revenue: ₹882 CrFY26 Planned Capex: ₹300 CrOperating Profit Margin (TTM): 39.4%Contract Value: not disclosed
📅 Short termThe announcement is likely to be viewed positively by the market as it demonstrates business development momentum despite recent stock underperformance.
📈 Long termStructurally significant as it secures a long-term off-take partner, supporting the company's 25% targeted growth rate and diversification away from core phenol-linked products.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Contract value and volume commitments not disclosed
- Potential margin pressure if raw material (Phenol) price pass-through lags
- Client concentration risk within the food/feed segment
Key Highlights
Initial contract term of 5 years established for long-term supply.
Designated as a 'substantial primary supplier' for Kemin Industries' food and feed business.
Supports the company's FY26 growth strategy involving ₹300 Cr in greenfield capex.
Aims to stabilize revenue after a 12-month price return of -39.2% and declining annual revenue.
Leverages existing 'Clean Technology' moat to serve global specialty chemical markets.
👀 What to Watch
Investors should monitor upcoming quarterly results for commentary on the volume commitments and margin profile of this contract. The key metric to watch is the utilization rate of the new HALS and performance chemical capacities funded by the ₹300 Cr FY26 capex.
0.53 GW Commissioned in Q1; CleanMax Targets ₹3,000 Cr EBITDA by FY28
CleanMax reported its largest-ever quarterly commissioning of 0.53 GW in Q1 FY27, exceeding the 0.42 GW commissioned during the entire FY25. The company is on track to meet its 1.5 GW annual capacity addition guidance, having already achieved 40% of its STU/Onsite target in three months. A significant pivot toward Data & AI customers now accounts for 42% (2.5 GW) of the total 6 GW contracted capacity. Management has issued a forward guidance of minimum ₹3,000 Cr EBITDA for FY 2027-28, supported by a reduced cost of debt at 8.4%.
Confidence: HIGH
What changedCleanMax has transitioned from annual-scale commissioning to quarterly-scale execution, while simultaneously shifting its portfolio heavily toward high-demand Data & AI customers.
Why it mattersThe company is scaling rapidly to meet India's projected tripling of data center capacity by 2030, which requires massive renewable energy and storage infrastructure.
Q1 Commissioned Capacity: 0.53 GWTotal Contracted Capacity: 6,003 MWFY28 EBITDA Guidance: ₹3,000 CrCost of Project Debt: 8.4%Data & AI Portfolio Share: 42%FY27 Capacity Addition Target: 1.5 GW
📅 Short termPositive sentiment expected as the company is ahead of its 'run-rate' for FY27 capacity targets and has secured 100% land for remaining contracted capacity.
📈 Long termStructural growth is tied to the ₹40,000 crore renewable capex opportunity per GW of data center load, where CleanMax holds a 35%+ market share in recent hyperscaler deals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for large-scale CTU projects in H2
- High steady-state Net Debt/EBITDA target of 5x to 5.5x
- Regulatory risks associated with STU connected group captive plants across 7 states
Key Highlights
Commissioned 0.53 GW in Q1 FY27, surpassing the 0.42 GW commissioned in the full year of FY25
Total contracted RE power sales capacity reached 6,003 MW (6 GW) as of June 30, 2026
Data & AI contracted capacity grew 10x from 0.24 GW in March 2024 to 2.5 GW in June 2026
Weighted average cost of project borrowing reduced from 9.2% to 8.4% over the last 15 months
Management provided a minimum EBITDA guidance of ₹3,000 Cr for FY 2027-28
👀 What to Watch
Watch for the execution of the 534 MW CTU-connected project in Karnataka scheduled for H2 FY27 and the maintenance of the Net Debt/EBITDA ratio within the 5x-5.5x target range.
CleanMax Q1 FY27: PAT turns positive at ₹55.2 cr; Operational capacity hits 3.5 GW
CleanMax reported a strong turnaround in Q1 FY27, posting a Profit After Tax (PAT) of ₹55.2 cr compared to a loss of ₹16.6 cr in Q1 FY26. Revenue from operations surged to ₹832.2 cr, nearly doubling from the ₹422.5 cr reported in Dec 2025. The company's operational capacity reached 3.5 GW, a 31% YoY growth, while total contracted capacity stands at 6.0 GW. Notably, 42% of contracted capacity is now tied to the high-growth Data & AI sector, providing a stable long-term revenue driver.
Confidence: HIGH
What changedCleanMax has transitioned from a loss-making entity to profitability while significantly scaling its operational asset base and reducing its cost of debt.
Why it mattersThe shift to profitability and the high concentration of Data Center clients (42%) validates the company's business model in the specialized C&I renewable energy space, which typically offers better margins than utility-scale projects.
Q1 FY27 Revenue: ₹832.2 crQ1 FY27 PAT: ₹55.2 crOperational Capacity: 3.5 GWContracted Capacity: 6.0 GWRevenue growth vs Dec 2025: 97%
📅 Short termThe stock is likely to react positively to the turnaround in PAT and the substantial jump in quarterly revenue and EBITDA margins.
📈 Long termThe company is structurally well-positioned with a 13 GW total portfolio (including advanced stages) and high customer stickiness, evidenced by 79% repeat business.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Grid backdowns expected in the 525 MW Rajasthan project for 6-12 months due to transmission upgrades
- High debt levels (₹10,280 cr run-rate net debt)
Key Highlights
Operational RE Power Sales capacity reached 3.5 GW, up from 1.7 GW in March 2025.
Adjusted EBITDA grew 74% YoY to ₹494 cr, with RE Power Sales margins improving to 83.7%.
Data & AI customers now account for 42% of the 6.0 GW contracted RE power sales capacity.
Cost of project debt reduced to 8.4% from 9.1% in June 2025, improving interest coverage.
Commissioned 0.4 GW of capacity in Q1 FY27 alone across 5 Indian states.
👀 What to Watch
Watch for the execution of the 2.5 GW 'contracted yet to be executed' pipeline, with at least 1.5 GW targeted for commissioning within FY27. Investors should also monitor the impact of transmission system upgrades in Rajasthan on the 525 MW CTU project's output.
107% Revenue Growth in Q1 FY27; Contracted Portfolio Reaches 6.8 GW
CleanMax reported a strong Q1 FY27 with revenue from operations more than doubling to ₹832 crore, driven by a larger operational asset base and a 632% surge in RE Services revenue. The company achieved a turnaround in profitability with a reported PAT of ₹55 crore, compared to a loss of ₹17 crore in the same quarter last year. A record 0.5 GW of capacity was commissioned during the quarter, bringing the total contracted portfolio to 6.8 GW. The company has provided guidance for adding over 1.5 GW of RE Power Sales capacity in FY27.
Confidence: HIGH
What changedCleanMax transitioned from a net loss in Q1 FY26 to a ₹55 crore profit in Q1 FY27, while doubling its revenue and reaching a record commissioning milestone.
Why it mattersThe results demonstrate strong operating leverage as the portfolio scales, particularly within the high-margin Data Center and AI infrastructure segments which now dominate the order book.
Revenue from Operations (Q1 FY27): ₹832 crAdjusted EBITDA: ₹494 crReported PAT: ₹55 crTotal Contracted Portfolio: 6.8 GWFY27 Capacity Addition Guidance: >1.5 GWCost of Debt: 8.4%
📅 Short termThe stock is likely to react positively to the sharp turnaround in profitability and the record execution pace of 0.5 GW in a single quarter.
📈 Long termStructural growth is supported by a 23-year average PPA tenor and a massive shift toward serving AI/Data Center clients, which provides high revenue visibility.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the 2.5 GW capacity currently under execution
- Concentration risk with 42% of capacity tied to the Data Center/AI segment
Key Highlights
Revenue from operations grew 107% YoY to ₹832 crore in Q1 FY27.
Total contracted portfolio reached 6.8 GW, representing a 3x increase over the past two years.
Data Center and AI segment now accounts for 42% of contracted RE Power Sales capacity, growing 10x since March 2024.
Weighted average cost of project debt improved to 8.4% as of June 2026, down from 9.2% in April 2025.
Achieved record quarterly commissioning of over 0.5 GW operational capacity in Q1 FY27.
👀 What to Watch
Monitor the execution of the 1.5 GW capacity addition guidance for FY27 and the impact of the proposed domestic bond issuance on further reducing borrowing costs.
₹2,500 Cr NCD Issuance and Amalgamation of 4 Subsidiaries Approved
Cleanmax has approved a significant fundraise of up to ₹2,500 crore through Non-Convertible Debentures (NCDs) to fund capital expenditure and debt refinancing. The company is also consolidating its operations by merging four wholly-owned rooftop solar subsidiaries into the parent entity to improve operational efficiency. Additionally, the company confirmed the prepayment of ₹599 crore in high-cost (11.5%) debt using IPO proceeds and highlighted a strategic 51:49 partnership with Apple India in a group company.
Confidence: HIGH
What changedThe company is transitioning to a leaner corporate structure through amalgamation while simultaneously preparing for a massive ₹2,500 crore capital infusion.
Why it mattersThe fundraise represents approximately 39% of FY26 revenue, indicating a major growth phase; the debt prepayment and consolidation will likely improve margins and administrative efficiency.
Proposed NCD Issuance: ₹2,500 croreDebt Prepaid from IPO Proceeds: ₹599 croreApple India Stake in Clean Max Taurus: 49%FY26 Consolidated Revenue: ₹6,357.31 croreNCD Issuance vs FY26 Revenue: ~39.3%
📅 Short termPositive reaction expected due to the large-scale growth funding and the successful reduction of high-interest debt.
📈 Long termStructural consolidation of the rooftop business and the partnership with Apple India position the company for scalable growth in the renewable utility sector.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for new projects funded by the ₹2,500 crore NCDs
- Regulatory approval for the composite scheme of amalgamation
Key Highlights
Approved issuance of listed NCDs up to ₹2,500 crore on a private placement basis for capex and debt repayment.
Amalgamation of 4 subsidiaries with the parent company, which had a combined FY26 revenue of approximately ₹127.7 crore.
Prepaid ₹599 crore of 11.5% p.a. NCDs on April 2, 2026, significantly reducing interest burden.
Strategic investment partnership established with Apple India Private Limited in Clean Max Taurus (51:49 ratio).
Enhanced security cover for existing listed debentures from 0.7x to 1.0x of outstanding obligations.
👀 What to Watch
Watch for the specific deployment timeline of the ₹2,500 crore NCD proceeds into new renewable projects and the final NCLT approval for the subsidiary mergers.
Clean Science subsidiary signs exclusive HALS manufacturing deal; to acquire 25% Swiss firm stake
Clean Science's subsidiary, Clean-Fino Chem, has entered into a long-term strategic collaboration with Swiss-based Geneus Chem AG. The agreement grants the subsidiary exclusive worldwide manufacturing rights for advanced grades of Hindered Amine Light Stabilizers (HALS). In exchange for the collaboration, the subsidiary will receive warrants to acquire a 25% stake in Geneus Chem within four years at a nominal price. This move leverages Clean Science's manufacturing capabilities to support its high-growth HALS portfolio, which is a key part of its Rs 300 Cr FY26 capex plan.
Confidence: HIGH
What changedThe company secured exclusive global manufacturing rights for a partner's advanced chemical grades and a path to 25% equity ownership in that partner.
Why it mattersIt accelerates the company's diversification into high-margin HALS products, utilizing its existing manufacturing infrastructure and Swiss R&D without significant upfront cash outflow.
Stake to be acquired: 25%Warrant exercise period: 4 yearsGeneus Chem incorporation year: 2022Planned FY26 Capex: Rs 300 CrTTM Revenue: Rs 882 Cr
📅 Short termPositive sentiment is expected as the deal strengthens the company's specialty chemicals positioning and validates its HALS growth strategy.
📈 Long termSignificant structural potential if the advanced HALS grades achieve global adoption, given the exclusive manufacturing rights and equity upside.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Startup risk of the Swiss partner
- Execution risks in scaling new chemical chemistries
- Potential time lag before significant revenue contribution
Key Highlights
Exclusive worldwide manufacturing rights for advanced grades of HALS products granted to Clean-Fino Chem.
Option to acquire 25% of the share capital of Geneus Chem AG on a fully diluted basis via warrants.
Warrants are exercisable within a 4-year period from the date of issuance.
Geneus Chem AG is a Swiss startup incorporated in 2022, specializing in chemical R&D and consulting.
Agreement includes minimum offtake commitments and a defined pricing mechanism for manufacturing.
👀 What to Watch
Monitor the commencement of production for these advanced HALS grades and their contribution to the HALS segment's revenue, which recently grew 34% in value.
530 MW Commissioned in Q1 FY27: CleanMax Operational Portfolio Hits 4.2 GW
CleanMax achieved its highest-ever quarterly commissioning by adding ~530 MW of renewable energy capacity in Q1 FY27. This milestone increased the company's total operational portfolio by approximately 16.7%, growing from 3.6 GW in March 2026 to 4.2 GW by June 2026. The expansion was led by the RE Power Sales segment, which added 403 MW, while the RE Services segment added 126 MWp. The company maintains a strong forward outlook with a total contracted portfolio of 5.7 GW, supported by a high-quality client base including Meta, Apple, and Amazon.
Confidence: HIGH
What changedCleanMax transitioned ~530 MW of capacity from construction to operational status in Q1 FY27, marking its fastest quarterly execution to date.
Why it mattersThis expansion significantly increases the company's revenue-generating asset base by 16.7% in just three months, demonstrating strong execution capabilities and high demand from the corporate C&I segment.
Q1 FY27 Commissioning: ~530 MWTotal Operational Portfolio: ~4.2 GWPortfolio Growth (QoQ): ~16.7%Total Contracted Portfolio: 5.7 GWData Centre/AI Customer Share: 42%
📅 Short termThe record commissioning is likely to be viewed positively by the market as it validates the company's ability to scale operations and meet rising corporate demand.
📈 Long termThe shift toward high-growth sectors like Data Centres and AI, combined with a large contracted pipeline, provides strong long-term cash flow visibility and structural growth potential.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risks across multiple state jurisdictions
- Concentration risk with 42% exposure to Data Centre/AI segments
Key Highlights
Commissioned a record ~530 MW of renewable energy capacity in a single quarter (Q1 FY27)
Total operational portfolio expanded to ~4.2 GW, up from ~3.6 GW as of March 2026
RE Power Sales portfolio reached ~3.5 GW following the addition of 403 MW during the quarter
Data Centres and AI infrastructure customers now contribute 42% of the contracted RE Power Sales portfolio
Geographic execution was led by Gujarat (~170 MW), Karnataka (~160 MW), and Maharashtra (~110 MW)
👀 What to Watch
Investors should monitor the pace at which the remaining ~1.5 GW of contracted capacity (5.7 GW total contracted vs 4.2 GW operational) is commissioned, as this will drive future revenue growth.
Rs 2,235 Cr Related Party Transactions Proposed for Approval at Clean Max July 24 AGM
Clean Max Enviro Energy Solutions has scheduled its 16th AGM for July 24, 2026, to approve FY26 financial statements and several material Related Party Transactions (RPTs). The company is seeking shareholder approval for transactions totaling Rs 2,235.38 crore across three subsidiaries: Clean Max Ajanta (Rs 876.77 cr), Clean Max Terra (Rs 858.61 cr), and Clean Max Vayu (Rs 500 cr). These limits are substantial, representing over 500% of the company's reported Dec 2025 quarterly revenue of Rs 422.46 crore. Other agenda items include the appointment of secretarial auditors for a five-year term and ratification of cost auditor fees.
Confidence: HIGH
What changedThe company has formally scheduled its 16th AGM and disclosed specific, high-value transaction limits for its key subsidiaries for the upcoming period.
Why it mattersThe magnitude of the proposed Related Party Transactions (totaling Rs 2,235.38 cr) relative to recent quarterly revenue (Rs 422.46 cr) indicates significant project execution and financial inter-dependence within the group's SPV structure.
Total Proposed RPT Limit: Rs 2,235.38 croreDec 2025 Quarterly Revenue: Rs 422.46 croreTotal RPT vs Dec 2025 Revenue: ~529%Cost Auditor Remuneration: Rs 1,75,000
📅 Short termNeutral; the stock may see limited movement until the AGM results and full FY26 financial statements are analyzed by the market.
📈 Long termThe scale of transactions suggests an aggressive expansion or operational phase through subsidiaries, which is structural for renewable energy firms but requires high governance standards.
⚠ Risk flags
- High value of Related Party Transactions relative to revenue
- Concentration of business within subsidiary SPVs
Key Highlights
Proposed Related Party Transaction limit of Rs 876.77 crore with Clean Max Ajanta Private Limited
Proposed Related Party Transaction limit of Rs 858.61 crore with Clean Max Terra Private Limited
Proposed Related Party Transaction limit of Rs 500.00 crore with Clean Max Vayu Private Limited
Ratification of Cost Auditor remuneration at Rs 1,75,000 for the financial year 2026-27
Appointment of M/s. BNP & Associates as Secretarial Auditors for a 5-year term (2026-2031)
👀 What to Watch
Investors should review the voting results of the AGM and the detailed annual report to understand the nature of these large-scale transactions with subsidiaries and ensure they are conducted at arm's length.
Clean Science Invests ₹50 Crore in Subsidiary Clean Fino-Chem for Project Funding
Clean Science and Technology Limited has infused ₹50 crore into its wholly-owned subsidiary, Clean Fino-Chem Limited (CFCL), by subscribing to a rights issue. The capital is specifically earmarked to fund ongoing projects in the specialty chemicals sector, indicating a focus on capacity building. CFCL has demonstrated rapid growth, with its annual turnover surging from ₹1.92 crore in FY24 to ₹166 crore in FY26. This continuous capital infusion reflects the parent company's strategy to scale its subsidiary's operations to drive future consolidated growth.
Key Highlights
Investment of ₹50.00 crore through the subscription of 8,36,121 equity shares at a premium of ₹588 per share.
Subsidiary turnover grew significantly from ₹1.92 crore in FY24 to ₹166 crore in FY26.
Capital infusion is intended to provide necessary funding for CFCL's upcoming manufacturing projects.
Clean Science maintains 100% ownership and control of Clean Fino-Chem Limited post-investment.
👀 What to Watch
Investors should monitor the progress of CFCL's new projects as the subsidiary is becoming a material contributor to the company's total revenue. The consistent capital support suggests strong management confidence in the specialty chemicals expansion.
Clean Max Approves Corporate Guarantees Worth ₹474.27 Crore for Five Subsidiaries
Clean Max Enviro Energy Solutions has approved the issuance of corporate guarantees totaling ₹474.27 crore to support term loan facilities for five of its subsidiary companies. The largest guarantee of ₹372.21 crore is directed towards Clean Max Theia Private Limited, while the remaining amount is distributed among four other subsidiaries. These guarantees are provided at arm's length and will be recorded as contingent liabilities on the company's consolidated balance sheet. While this increases the parent company's risk exposure, it facilitates necessary funding for subsidiary operations and expansion.
Key Highlights
Total corporate guarantees issued amount to ₹474.27 crore across five subsidiaries
Clean Max Theia Private Limited receives the highest allocation of ₹372.21 crore
Guarantees support term loan facilities for Clean Max Arctic, Fuji, Aero, and Godavari subsidiaries
The transactions are conducted at arm's length with no promoter group interest
The guarantees represent contingent liabilities for the listed entity with no immediate financial impact
👀 What to Watch
Investors should monitor the performance of the subsidiaries and the parent company's total contingent liabilities relative to its net worth. This move is standard for supporting subsidiary growth but increases the parent's risk profile in case of subsidiary defaults.
